The HMGXB4 Knockout NCI-H1975 Polyclonal Cells is a CRISPR/Cas9-edited polyclonal knockout cell population with disruption of the HMGXB4 gene in the NCI-H1975 lung adenocarcinoma cell line. This polyclonal pool provides a heterogeneous loss-of-function model to investigate HMGXB4’s role in NSCLC biology, enabling studies of its contributions to transcriptional regulation, proliferation, and signaling in a disease-relevant context.
The NCI-H1975 cell line is a lung adenocarcinoma model from a female patient, harboring EGFR L858R and T790M mutations. These mutations confer resistance to first-generation EGFR inhibitors, making it valuable for studying acquired resistance and evaluating next-generation inhibitors like osimertinib. It retains epithelial characteristics and growth factor responsiveness, offering a suitable platform for oncogenic pathway studies.
HMGXB4 encodes an HMG-box-containing transcriptional regulator that binds DNA and modulates chromatin architecture. As a cofactor, it interacts with ??-catenin and TCF/LEF transcription factors (including TCF7L2 and LEF1) to regulate Wnt target gene expression. Upstream signals such as Wnt ligands (e.g., WNT3A) and EGF activate these pathways, resulting in transcriptional regulation of downstream targets like CCND1, MYC, and AXIN2. Additionally, HMGXB4 associates with chromatin remodeling complexes, positioning it at the nexus of Wnt and EGFR signaling.
In NCI-H1975 cells, HMGXB4 knockout provides a system to examine its role in lung adenocarcinoma. The EGFR L858R/T790M mutations create a signaling context where Wnt/??-catenin activity may influence drug sensitivity and proliferation. Disrupting HMGXB4 allows assessment of its requirement for Wnt target gene expression, its effect on ??-catenin-dependent transcription, and its potential involvement in EGFR inhibitor resistance. The polyclonal population retains cellular heterogeneity, better recapitulating tumor clonal diversity.
This polyclonal knockout cell population is suitable for diverse experimental applications. Western blotting, RT-qPCR, and RNA-seq can validate knockout and profile transcriptional changes. Co-immunoprecipitation assays can map interactions with ??-catenin, TCF7L2, or chromatin remodeling complexes. Functional assays including proliferation, colony formation, and migration reveal phenotypic consequences of HMGXB4 loss. Drug sensitivity testing with osimertinib, combined with TCF/LEF luciferase reporter assays, enables exploration of EGFR-Wnt crosstalk. For further information or custom projects, please contact Ascent Research.
